Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHB036C and MHB039A in Advanced Breast Cancer and Solid Tumors
NCT07130383Phase 2Recruiting
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Sep 2025
- Primary completion
- Aug 2029
- Modality
- Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of MHB036C, MHB039A in breast cancer, solid tumor, sponsored by Minghui Pharmaceutical, Inc.. Started Sep 2025; status: recruiting.
02
Drugs
MHB036CMHB039A
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT07130383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07130383.